Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | hydroxyprostaglandin dehydrogenase 15-(NAD) | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | steroid dehydrogenase, putative | hydroxyprostaglandin dehydrogenase 15-(NAD) | 266 aa | 216 aa | 22.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | choline O acetyltransferase | 0.0046 | 0.0724 | 0.1288 |
Brugia malayi | Choline O-acetyltransferase | 0.0046 | 0.0724 | 0.0673 |
Echinococcus multilocularis | lamin | 0.0033 | 0.0409 | 0.0717 |
Schistosoma mansoni | choline o-acyltransferase | 0.0046 | 0.0724 | 1 |
Schistosoma mansoni | choline o-acyltransferase | 0.0046 | 0.0724 | 1 |
Loa Loa (eye worm) | carnitine O-palmitoyltransferase I isoform | 0.0046 | 0.0724 | 0.0724 |
Echinococcus multilocularis | choline O acetyltransferase | 0.0046 | 0.0724 | 0.1288 |
Echinococcus multilocularis | musashi | 0.0033 | 0.0409 | 0.0717 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.0409 | 0.0409 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.0409 | 0.0357 |
Trypanosoma brucei | carnitine O-palmitoyltransferase, putative | 0.0046 | 0.0724 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0409 | 0.0409 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0014 | 0.0014 |
Loa Loa (eye worm) | choline/Carnitine O-acyltransferase | 0.0046 | 0.0724 | 0.0724 |
Onchocerca volvulus | 0.0046 | 0.0724 | 1 | |
Trypanosoma brucei | hypothetical protein, conserved | 0.0046 | 0.0724 | 0.5 |
Echinococcus granulosus | lamin | 0.0033 | 0.0409 | 0.0717 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0251 | 0.5525 | 1 |
Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.0046 | 0.0724 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.0409 | 0.0717 |
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.0724 | 0.0724 |
Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.0046 | 0.0724 | 0.0673 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.0409 | 0.0717 |
Loa Loa (eye worm) | hypothetical protein | 0.0442 | 1 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.0409 | 0.0717 |
Brugia malayi | Choline/Carnitine o-acyltransferase family protein | 0.0046 | 0.0724 | 0.0673 |
Trypanosoma brucei | carnitine O-acetyltransferase, putative | 0.0046 | 0.0724 | 0.5 |
Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.0046 | 0.0724 | 0.5 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0055 | 0.0055 |
Onchocerca volvulus | 0.0046 | 0.0724 | 1 | |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.0409 | 0.0357 |
Echinococcus granulosus | carnitine O palmitoyltransferase 1 liver | 0.0251 | 0.5525 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.0409 | 0.0409 |
Echinococcus multilocularis | carnitine O palmitoyltransferase 1, liver | 0.0251 | 0.5525 | 1 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0251 | 0.5525 | 1 |
Leishmania major | choline/Carnitine o-acyltransferase-like protein | 0.0251 | 0.5525 | 1 |
Onchocerca volvulus | 0.0046 | 0.0724 | 1 | |
Onchocerca volvulus | 0.0046 | 0.0724 | 1 | |
Echinococcus multilocularis | carnitine O palmitoyltransferase 2 | 0.0046 | 0.0724 | 0.1288 |
Loa Loa (eye worm) | choline O-acetyltransferase | 0.0046 | 0.0724 | 0.0724 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0395 | 0.0395 |
Brugia malayi | Choline O-acetyltransferase | 0.0046 | 0.0724 | 0.0673 |
Echinococcus granulosus | carnitine O palmitoyltransferase 2 | 0.0046 | 0.0724 | 0.1288 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase). (Class of assay: confirmatory) [Related pubchem assays: 2429 (Confirmation qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2407 (Probe Development Summary for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2427 (Thermal Shift Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase))] | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 17.7828 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.